يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Receptors, Thromboxane antagonists & inhibitors"', وقت الاستعلام: 0.77s تنقيح النتائج
  1. 1
    The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin

    المؤلفون: Pierre Fontana, A Santana Sorensen, Pēteris Alberts, Henri Bounameaux, J-P Meyer, Kjell S Sakariassen

    المصدر: Journal of Thrombosis and Haemostasis, Vol. 9, No 10 (2011) pp. 2109-11

    مصطلحات موضوعية: medicine.medical_specialty, Receptors, Thromboxane, Pharmacology, Thromboxane receptor antagonist, Internal medicine, medicine, Platelet Aggregation Inhibitors/pharmacology, Humans, Platelet, Enzyme Inhibitors, ddc:616, Enzyme Inhibitors/pharmacology, Aspirin, biology, Chemistry, Hematology, Receptors, Thromboxane/antagonists & inhibitors, Endocrinology, biology.protein, Platelet aggregation inhibitor, Thromboxane-A synthase, Thromboxane-A Synthase, Thromboxane-A Synthase/antagonists & inhibitors, Function (biology), Aspirin/pharmacology, Platelet Aggregation Inhibitors, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3adf8bc87781737fb929649640cd1a4
    https://pubmed.ncbi.nlm.nih.gov/21777369

    View record at Wiley
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.

    المؤلفون: Ghuysen, Alexandre, Dogné, Jean-Michel, Chiap, Patrice, Rolin, Stephanie, Masereel, Bernard, Lambermont, Bernard, Kolh, Philippe, Tchana-Sato, Vincent, Hanson, Julien, D'Orio, Vincenzo

    المصدر: Cardiovascular Drug Reviews, 23 (1), 1-14 (2005)

    مصطلحات موضوعية: Animals, Humans, Receptors, Thromboxane/antagonists & inhibitors/therapeutic use, Sulfonylurea Compounds/chemical synthesis/pharmacology/therapeutic use, Thromboxane-A Synthase/antagonists & inhibitors/pharmacology/therapeutic use, Human health sciences, Pharmacy, pharmacology & toxicology, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie

    Relation: urn:issn:0897-5957; urn:issn:1527-3466

    URL الوصول: https://orbi.uliege.be/handle/2268/7326

    أضف إلى المفضلة
  3. 3
    مورد إلكتروني
    Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

    المصدر: Cerebrovascular diseases, 27 (5

    مصطلحات الفهرس: Sciences bio-médicales et agricoles, Aged, Aged, 80 and over, Aspirin -- adverse effects, Aspirin -- therapeutic use, Cardiovascular Diseases -- etiology, Cardiovascular Diseases -- prevention & control, Dose-Response Relationship, Drug, Double-Blind Method, Endpoint Determination, Female, Humans, International Cooperation, Ischemic Attack, Transient -- complications, Ischemic Attack, Transient -- drug therapy, Male, Middle Aged, Naphthalenes -- adverse effects, Naphthalenes -- therapeutic use, Platelet Aggregation Inhibitors -- adverse effects, Platelet Aggregation Inhibitors -- therapeutic use, Propionic Acids -- adverse effects, Propionic Acids -- therapeutic use, Receptors, Thromboxane -- antagonists & inhibitors, Stroke -- complications, Stroke -- drug therapy, Stroke -- etiology, Stroke -- prevention & control, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article

    URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/56434
    http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL

    أضف إلى المفضلة
  4. 4
    مورد إلكتروني
    Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

    المصدر: Cerebrovascular diseases, 27 (5

    مصطلحات الفهرس: Sciences bio-médicales et agricoles, Aged, Aged, 80 and over, Aspirin -- adverse effects, Aspirin -- therapeutic use, Cardiovascular Diseases -- etiology, Cardiovascular Diseases -- prevention & control, Dose-Response Relationship, Drug, Double-Blind Method, Endpoint Determination, Female, Humans, International Cooperation, Ischemic Attack, Transient -- complications, Ischemic Attack, Transient -- drug therapy, Male, Middle Aged, Naphthalenes -- adverse effects, Naphthalenes -- therapeutic use, Platelet Aggregation Inhibitors -- adverse effects, Platelet Aggregation Inhibitors -- therapeutic use, Propionic Acids -- adverse effects, Propionic Acids -- therapeutic use, Receptors, Thromboxane -- antagonists & inhibitors, Stroke -- complications, Stroke -- drug therapy, Stroke -- etiology, Stroke -- prevention & control, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article

    URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/56434
    http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء